HeartSciences Inc. (NASDAQ:HSCS) Short Interest Update

HeartSciences Inc. (NASDAQ:HSCS) saw a large growth in short interest in August. As of August 31st, there was short interest totaling 114,152 shares, a growth of 125.2% from the August 15th total of 50,682 shares. Based on an average daily volume of 167,140 shares, the short-interest ratio is currently 0.7 days. Approximately 3.1% of the company’s stock are short sold.

HeartSciences Stock Down 2.8%

Shares of HeartSciences stock opened at $3.44 on Wednesday. HeartSciences has a 12-month low of $1.63 and a 12-month high of $4.35. The stock has a 50 day moving average price of $2.70 and a two-hundred day moving average price of $2.39. The stock has a market capitalization of $13.42 million, a P/E ratio of -1.07 and a beta of 1.85.

HeartSciences (NASDAQ:HSCS) last released its quarterly earnings results on Monday, September 14th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14). The firm had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.10 million. Sell-side analysts anticipate that HeartSciences will post -3.04 earnings per share for the current year.

Analyst Ratings Changes

HSCS has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. Wall Street Zen upgraded shares of HeartSciences to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, HeartSciences currently has an average rating of “Hold” and a consensus target price of $8.00.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non?invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high?fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high?frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.